Moderna slides as investors digest recent surge and reassess near-term catalysts

Moderna, Inc. (MRNA) is down 4.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a pullback after a very sharp recent rally, with investors taking profits following Moderna’s re-entry into the Nasdaq-100 and a run that had already priced in a lot of optimism around its pipeline. This could also reflect lingering valuation concerns after a bearish analyst call last week and the market’s tendency to fade event-driven gains once index-related buying is complete.

Details:

Nasdaq announced on October 1 that Moderna would join the Nasdaq-100 before the market opened on October 9, creating a short-term catalyst tied to index-related demand.

By October 9, the stock had surged roughly 12% to about $220 and reached its highest level since January 2022, suggesting the shares had become extended going into this week.

Recent commentary in the market has focused on whether Moderna’s powerful rally already reflects much of the expected value from its oncology and vaccine pipeline, leaving the stock vulnerable to profit-taking.

Moderna’s latest quarterly update still showed modest second-quarter revenue and a GAAP net loss, even as management reiterated its 2026 growth framework and highlighted upcoming pipeline milestones.

Sources:

Nasdaq, SEC, Reuters

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRNA Insider Trading Activity

$MRNA insiders have traded $MRNA stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
STEPHEN HOGE (President) has made 0 purchases and 5 sales selling 240,583 shares for an estimated $20,618,266.
JAMES M MOCK (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,836 shares for an estimated $4,685,093.
SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,942 shares for an estimated $659,316.
NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MRNA Hedge Fund Activity

We have seen 374 institutional investors add shares of $MRNA stock to their portfolio, and 321 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 6,187,867 shares (+13.5%) to their portfolio in Q2 2026, for an estimated $433,336,326
D. E. SHAW & CO., INC. removed 5,157,808 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $361,201,294
PRICE T ROWE ASSOCIATES INC /MD/ added 4,850,982 shares (+656.8%) to their portfolio in Q2 2026, for an estimated $339,714,269
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,838,884 shares (+inf%) to their portfolio in Q2 2026, for an estimated $338,867,046
CAPITAL WORLD INVESTORS added 3,579,302 shares (+19.1%) to their portfolio in Q2 2026, for an estimated $250,658,519
ALYESKA INVESTMENT GROUP, L.P. removed 3,490,366 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $244,430,330
BAILLIE GIFFORD & CO removed 2,373,736 shares (-11.5%) from their portfolio in Q2 2026, for an estimated $166,232,732

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRNA Congressional Stock Trading

Members of Congress have traded $MRNA stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by members of Congress over the last 6 months:

REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 3 times. They made 1 purchase worth up to $15,000 on 08/19 and 2 sales worth up to $30,000 on 09/24, 08/19.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MRNA Price Targets

Multiple analysts have issued price targets for $MRNA recently. We have seen 7 analysts offer price targets for $MRNA in the last 6 months, with a median target of $45.0.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
Eliana Merle from UBS set a target price of $45.0 on 05/04/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.